Trial Profile

A FIRST-IN-HUMAN PHASE 1, DOSE ESCALATION, SAFETY AND PHARMACOKINETIC STUDY OF PF-06647020 IN ADULT PATIENTS WITH ADVANCED SOLID TUMORS

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 06 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cofetuzumab pelidotin (Primary) ; Avelumab; Fluconazole
Indications Advanced breast cancer; Non-small cell lung cancer; Ovarian cancer; Solid tumours
Focus Adverse reactions; First in man
Sponsors Pfizer

Most Recent Events

03 Jun 2021 Results assessing the safety, tolerability, pharmacokinetics, dose-escalation and antitumor activity of cofetuzumab pelidotin in patients with advanced solid tumors, published in the Clinical Cancer Research.
08 Nov 2019 Status changed from active, no longer recruiting to completed.
12 Oct 2019 Planned End Date changed from 20 Sep 2019 to 4 Nov 2019.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com